Articles From: SAP® Solutions for Retail Drive Omni-Channel Customer Experience to Sarepta Therapeutics to Present Company Overview at Canaccord Annual Growth Conference


2014/9/24
SAP Supports Customers to Better Understand Buying Behavior and Offer a Seamless Shopping Experience Across All Devices, Channels and Touch Points WALLDORF, Germany , Sept.
Sign-up for SAP® Solutions for Retail Drive Omni-Channel Customer Experience investment picks
Post-acquisition, Sapiens will offer a holistic, end-to-end decision management solution HOLON, Israel , July 30, 2014 /PRNewswire/ -- Sapiens International Corporation , (NASDAQ and TASE: SPNS), a leading global provider of software solutions for the insurance industry, with an emerging focus on the broader financial services sector, today announced it has acquired Knowledge Partners International (KPI), a pioneer and recognized leader in decision management consultancy, services and training.
Sign-up for Sapiens Acquires KPI, Owner of "The Decision Model" Patent and a Leading Decision Management Consultancy Firm investment picks
2014/8/12
Non-GAAP Operating Profit increased by 19.6% HOLON, Israel , Aug.
Sign-up for Sapiens Reports Record Quarterly Revenue of $38.6 Million, Up 16.9% Year-Over-Year investment picks
2014/7/28
HOLON, Israel , July 28, 2014 /PRNewswire/ -- Sapiens International Corporation , (NASDAQ and TASE: SPNS), a leading global provider of software solutions for the insurance industry, with an emerging focus on the broader financial services sector, announced today that it will report its financial results for the second quarter ended June 30, 2014 on Tuesday, August 12, 2014 .
Sign-up for Sapiens to Announce Second Quarter 2014 Financial Results on Tuesday, August 12, 2014 investment picks
2014/8/12
HOLON, Israel , August 12, 2014 /PRNewswire/ -- Sapiens International Corporation , (NASDAQ and TASE: SPNS), a leading global provider of software solutions for the insurance industry, with an emerging focus on the broader financial services sector, announced today that it will host a conference call to discuss its second quarter financial results, today, August 12 th , at 9:30 a.m. Eastern Time ( 4:30 p.m. Israel Time). Please call the following numbers (at least 10 minutes before the scheduled time) in order to participate: North America toll-free: +1-888-407-2553 ; International: +972-3-918-0644 ; UK: 0800-917-5108 (Logo: http://photos.prnewswire.com/prnh/20120508/531104 ) The live webcast of the call will also be accessible on Sapiens Website at: http://www.sapiens.com/webcasts-presentations.htm .
Sign-up for Sapiens to Host a Conference Call Today to Discuss Q2 2014 Financial Results investment picks
Sapient Global Markets , a division of Sapient (NASDAQ: SAPE), and a leading global provider of business technology and consulting services for the capital and commodity markets, and OpenLink, a leading provider of software for the commodity and energy industries, today announced a new collaboration around the OpenLink IRM platform.
Sign-up for Sapient Global Markets and OpenLink Announce Collaboration to Enhance Portfolio and Asset Optimization for Energy Market Participants investment picks
Sapient Global Markets , a division of Sapient (NASDAQ: SAPE), and a leading global provider of business technology and consulting services for the capital and commodity markets, today announced further enhancements to its Compliance Management and Reporting System (CMRS) to support collateral and valuation reporting.
Sign-up for Sapient Global Markets Supports EMIR Collateral and Valuation Reporting Through CMRS Enhancements investment picks
Sapient (NASDAQ: SAPE) today reported the following financial results for the second quarter ended June 30, 2014: “We are very pleased with the results we’ve posted in the first half of 2014 despite the challenging economic environment,” said Sapient Chief Executive Officer and Co-Chairman Alan J.
Sign-up for Sapient Reports Second Quarter 2014 Results investment picks
Sapient (NASDAQ: SAPE) today announced that it will release results for the second quarter ended June 30, 2014 on Wednesday, August 6, 2014 after the close of regular market hours.
Sign-up for Sapient to Announce Second Quarter Financial Results on August 6 investment picks
Sapient (NASDAQ: SAPE) today announced that Alan J.
Sign-up for Sapient to Present at Citi Global Technology Conference investment picks
2014/7/16
JOHANNESBURG, South Africa, July 16, 2014 /PRNewswire/ -- Sappi today confirmed that they have concluded the sale of Sappi's Usutu Forest Products Company Limited to local Swaziland business Montigny Investments.
Sign-up for Sappi confirms purchase by Montigny Investments of Sappi's Usutu business in Swaziland investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0961390001&sourceType=1 http://www.ccnmatthews.com/logos2/saputo.gif MONTREAL, QUEBEC --
Sign-up for Saputo Announces Election of Directors investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0960920001&sourceType=1 http://www.ccnmatthews.com/logos2/saputo.gif MONTREAL, QUEBEC --
Sign-up for Saputo Inc.: Financial Results for Fiscal 2015 First Quarter Ended June 30, 2014 investment picks
Hawker Energy, Inc. (OTCQB:HWKR) (the “Company”) is pleased to announce it has changed its name from Sara Creek Gold Corp.
Sign-up for Sara Creek Gold Corp. Announces Name and Ticker Symbol Change to Hawker Energy, Inc. (OTCQB:HWKR) investment picks
2014/10/8
Save room for dessert! Today two new flavors join the iconic Sara Lee ® Desserts pound cake product line: Blueberry Pound Cake and Gingerbread Pound Cake.
Sign-up for Sara Lee® Desserts Sweetens Pound Cake Portfolio with Two New Flavors investment picks
SAN RAFAEL, Calif., July 23, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Sarah Cannon Research UK today announced a collaboration to enroll patients in an ongoing Phase 3 clinical trial of its PARP inhibitor, BMN 673, for the treatment of hereditary breast cancer with a BRCA mutation.
Sign-up for Sarah Cannon Research UK and BioMarin Collaborate on EMBRACA Clinical Study in Hereditary Breast Cancer With BRCA Mutation investment picks
2014/8/18
Nordstrom-exclusive collection includes riding boots, pumps, and new handbags SEATTLE , Aug.
Sign-up for Sarah Jessica Parker's SJP Collection Available in Five Additional Nordstrom Stores for Fall 2014 investment picks
2014/10/6
Sarah McLachlan School of Music hits high note with $300,000 donation from Sun Life Financial Canada NewsWire VANCOUVER , Oct.
Sign-up for Sarah McLachlan School of Music hits high note with $300,000 donation from Sun Life Financial investment picks
NEW YORK , July 14, 2014 /PRNewswire/ -- Saratoga Investment Corp.
Sign-up for Saratoga Investment Corp. Announces Fiscal First Quarter 2015 Financial Results investment picks
Also Announces Dividend Reinvestment and Share Repurchase Plan NEW YORK , Sept.
Sign-up for Saratoga Investment Corp. to Pay Regular Cash Dividend investment picks
Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, and Flagship Biosciences LLC, a leading tissue-based companion diagnostics firm, today announced a multi-year, multi-product partnership for the development of automated quantitative endpoint measurements in muscular dystrophy to support the advancement of Sarepta’s Duchenne muscular dystrophy (DMD) drug pipeline, including its lead candidate, eteplirsen.
Sign-up for Sarepta Enters into Partnership with Flagship Biosciences to Digitally Automate the Measurement of Dystrophin, a Key Therapeutic Efficacy Marker for Muscular Dystrophy investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that John Hodgman, a member of Sarepta’s board of directors, has been named interim chairman, effective July 30, 2014.
Sign-up for Sarepta Therapeutics Announces Appointment of John Hodgman As Interim Chairman investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced favorable safety results from the single ascending dose portion of a Phase I study of AVI-7100, the company’s lead candidate for the treatment of influenza virus, in healthy volunteers.
Sign-up for Sarepta Therapeutics Announces Favorable Safety Results from Phase I Clinical Study of Influenza Drug Candidate investment picks
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced that it will give one oral presentation and two poster presentations on data from its ongoing Phase II and preclinical trials evaluating exon-skipping therapies for the treatment of Duchenne muscular dystrophy (DMD) at the International Congress of the World Muscle Society (WMS), being held from October 7-11, 2014, in Berlin, Germany.
Sign-up for Sarepta Therapeutics Announces Presentations at the 19th International Congress of the World Muscle Society investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today reported financial results for the three and six months ended June 30, 2014, and provided an update of recent corporate developments.
Sign-up for Sarepta Therapeutics Announces Second Quarter 2014 Financial Results and Recent Corporate Developments investment picks
2014/10/1
On the heels of news of the first case of Ebola on U.S. soil, the company that has developed a treatment for the deadly disease said it has enough doses to cover about 100 patients.
Sign-up for Sarepta Therapeutics CEO: We have just 100 doses to treat Ebola investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report second quarter 2014 financial results before the NASDAQ Global Market opens on Thursday, August 7, 2014.
Sign-up for Sarepta Therapeutics to Announce Second Quarter 2014 Financial Results and Corporate Update on August 7, 2014 investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that management is scheduled to participate in a fireside chat at the Leerink Partners Rare Disease Roundtable in New York on Wednesday, October 1, 2014, at 8:00 a.m. ET.
Sign-up for Sarepta Therapeutics to Present at Leerink Partners Rare Disease Roundtable investment picks
Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that management will present a company overview at the Canaccord 34 th Annual Growth Conference in Boston, MA on Wednesday, August 13, 2014, at 4:30 pm, ET.
Sign-up for Sarepta Therapeutics to Present Company Overview at Canaccord Annual Growth Conference investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: SAP® Solutions for Retail Drive Omni-Channel Customer Experience to Sarepta Therapeutics to Present Company Overview at Canaccord Annual Growth Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices